Enanta Pharmaceuticals to Present at Jefferies 2014 Global Healthcare
Presentation to be Webcast on June 2, 2014 at 8:30 A.M. ET
Jefferies 2014 Global Healthcare Conference
WATERTOWN, Mass. -- May 22, 2014
Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA) a research and development-focused
biotechnology company dedicated to creating small molecule drugs in the
infectious disease field, today announced that Jay R. Luly, Ph.D., President
and Chief Executive Officer, will present on Monday, June 2, 2014, at 8:30
a.m. ET during the Jefferies 2014 Global Healthcare Conference taking place in
A live webcast and replay of the presentation can be accessed by visiting the
“Calendar of Events” section on the “Investors” page of Enanta’s website at
www.enanta.com. A replay of the webcast will be available following the
presentation and will be archived for approximately 30 days.
Enanta Pharmaceuticals is a research and development-focused biotechnology
company that uses its robust chemistry-driven approach and drug discovery
capabilities to create small molecule drugs in the infectious disease field.
Enanta is discovering, and in some cases developing, novel inhibitors designed
for use against the hepatitis C virus (HCV). These inhibitors include members
of the direct acting antiviral (DAA) inhibitor classes – protease (partnered
with AbbVie), NS5A (partnered with Novartis) and nucleotide polymerase – as
well as a host-targeted antiviral (HTA) inhibitor class targeted against
cyclophilin. Additionally, Enanta has created a new class of antibiotics,
called Bicyclolides, for the treatment of multi-drug resistant bacteria, with
a focus on developing an intravenous and oral treatment for hospital and
community MRSA (methicillin-resistant Staphylococcus aureus) infections.
Enanta Pharmaceuticals, Inc.
Carol Miceli, 617-607-0710
Press spacebar to pause and continue. Press esc to stop.